RESUMEN
BACKGROUND: The H1N1 influenza pandemic had garnered a large amount of attention. Currently, the most effective preventive measure available is the H1N1 vaccine. We aimed to assess the willingness of our study participants to receive the H1N1 vaccination prior to the annual Hajj season. If any participant declined, we investigated the reasons for vaccine rejection. FINDINGS: We conducted a prospective cohort study of National Guard employees during the 1430 (2009) Hajj season. A survey was used as the primary method for data collection. Participants were vaccinated one to two weeks prior to their trip to Mona, and any side effects reported at the time of injection and three weeks post vaccination were recorded.There were 100 male and 26 female participants in the study. In total, 66.7% (n = 84) of the participants were health care workers (HCWs) and 33.3% (n = 42) were non-health care workers (non-HCWs). Less than half of the respondents (46.8%, n = 59) accepted the vaccination. The vaccination acceptance rate was higher among non-HCWs, at a rate of 71.4% (n = 30); HCWs only accepted at a rate of 34.5% (n = 29) (OR 1.103, 95% CI [0.488-2.496]). The most common reason for vaccine refusal was the impression that the disease was not fatal (25.4%, n = 32). Finally, all participants reported pain at the injection site and 18.3% (n = 11) reported swelling. All other side effects were reported in less than 15% of the participants. CONCLUSIONS: Despite fears of the new H1N1 vaccine, there was a reasonable rate of vaccine acceptance among our study participants. Early health education may increase the rate of acceptance of the H1N1 vaccine. Furthermore, additional research is needed on long-term adverse effects of the H1N1 vaccine.
RESUMEN
BACKGROUND: The annual Hajj pilgrimage to Mecca, Saudi Arabia brings over two million people to a small confined area. Respiratory tract infection is the most common disease transmitted during this period. For most of the etiologic agents of upper respiratory tract infections, no vaccine or prophylaxis is available, except for influenza. Yearly influenza vaccination of high-risk groups is recommended, but no special recommendations are available for those performing the Hajj or other similar large congregational activities. Viral surveillance studies are being carried out through more than 100 centers around the world to identify newly emerging viruses. Saudi Arabia is not one of those centers and no routine surveillance takes place. METHODS: Five hundred Hajj pilgrims presenting with upper respiratory tract symptoms from different parts of the world were screened by way of a throat swab for viral culture, including influenza A and B, parainfluenza, respiratory syncytial virus (RSV), adenovirus, herpes simplex virus (HSV), and enteroviruses. Information was collected on age, sex, nationality, smoking habits and upper respiratory tract symptoms. Vaccination status for influenza and meningococcus was obtained by self-declaration, since most pilgrims did not have their vaccination cards with them. Only those with symptoms including at least fever, reported by the patient to be >38.3 degrees C, and/or sore throat were included. Pilgrims with any other symptoms, especially myalgia and fatigue alone, were excluded, since many of the physical chores during the pilgrimage may contribute to such symptoms. RESULTS: Fifty-four patients (10.8%) had positive viral throat cultures. Of these, 27 (50%) were influenza B, 13 (24.1%) were HSV, 7 (12.9%) were RSV, 4 (7.4%) were parainfluenza, and 3 (5.6%) were influenza A. No enteroviruses or adenoviruses were detected, and no multiple infections were detected. Only 22 (4.7%) pilgrims received the influenza vaccine. When the results are applied to the total number of pilgrims in 2003, an estimate of 24,000 cases of influenza is obtained. CONCLUSION: The findings from this study suggest a high incidence of influenza as a cause of upper respiratory tract infection among pilgrims, estimated to be 24,000 cases per Hajj season, excluding those becoming ill from contact with Hajj pilgrims returning home. They also indicate a very low vaccination rate for the influenza vaccine; as well as poor knowledge of its existence. Continued surveillance during the Hajj pilgrimage is necessary. The influenza vaccine should be a priority for those attending the Hajj pilgrimage, and should also be considered for antiviral prophylaxis.